EUVIMEDEUVIMED entdecken
VergleichsstudieÜbersichtsarbeitOpen Access · CC BY 4.0

A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device

Hideaki Bando, Yoichi Naito, Tomoyuki Yamada, Takao Fujisawa, Mitsuho Imai, Yasutoshi Sakamoto, Yusuke Saigusa, Kouji Yamamoto, Yutaka Tomioka, Nobuyoshi Takeshita, Kuniko Sunami, Megumi Futamura und 4 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02684-z ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Hideaki Bando und 15 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Dev…. Hauptthemen laut MEDLINE: Artificial Intelligence, Neoplasms, Precision Medicine, Software. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, New Energy and Industrial Technology Development Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The implementation of cancer precision medicine in Japan is deeply intertwined with insurance reimbursement policies and requires case-by-case reviews by Molecular Tumor Boards (MTBs), which impose considerable operational burdens on healthcare facilities. The extensive preparation and review times required by MTBs hinder their ability to efficiently assess comprehensive genomic profiling (CGP) test results. Despite attempts to optimize MTB operations, significant challenges remain. This study aims to evaluate the effectiveness of QA Commons, an artificial intelligence-driven system designed to improve treatment planning using CGP analysis. QA Commons utilizes a comprehensive knowledge base of drugs, regulatory approvals, and clinical trials linked to genetic biomarkers, thereby enabling the delivery of consistent and standardized treatment recommendations. Initial assessments revealed that the QA Commons’ recommendations closely matched the ideal treatment recommendations (consensus annotations), outperforming the average results of MTBs at Cancer Genomic Medicine Core Hospitals.

Methods

A clinical performance evaluation study will be conducted by comparing the QA Commons’ treatment recommendations with those of the Academia Assembly, which includes medical professionals from the Cancer Genomic Medicine Core and Hub Hospitals. One hundred cases selected from the “Registry of the Academia Assembly,” based on defined inclusion and exclusion criteria, will be analyzed to assess the concordance of recommendations.

Conclusion

The expected outcomes suggest that QA Commons could reduce the workload of MTB members, standardize the quality of MTB discussions, and provide consistent outcomes in repeated patient consultations. In addition, the global expansion of QA Commons could promote worldwide adoption of Japan’s pioneering precision oncology system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceNeoplasmsPrecision MedicineSoftwareHumansProspective StudiesJapan

Stichwörter der Autor:innen

AI-powered diagnostic toolsCancer precision medicineComprehensive genomic profilingMolecular Tumor Board

Autor:innen und Institutionen

  • Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kas…
  • Division of Data Science, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital, East 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Genomedia Inc, 4-1-4 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Förderung

  • Japan Agency for Medical Research and Development
  • New Energy and Industrial Technology Development Organization

Zitieren

APA

Bando, H., Naito, Y., Yamada, T., Fujisawa, T., Imai, M., Sakamoto, Y., Saigusa, Y., Yamamoto, K., Tomioka, Y., Takeshita, N., Sunami, K., Futamura, M., Notake, C., Aoki, S., Okano, K., & Yoshino, T. (2025). A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02684-z

Vancouver

Bando H, Naito Y, Yamada T, Fujisawa T, Imai M, Sakamoto Y, et al. A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02684-z

BibTeX
@article{Bando2025,
  author = {Bando, Hideaki and Naito, Yoichi and Yamada, Tomoyuki and Fujisawa, Takao and Imai, Mitsuho and Sakamoto, Yasutoshi and Saigusa, Yusuke and Yamamoto, Kouji and Tomioka, Yutaka and Takeshita, Nobuyoshi and Sunami, Kuniko and Futamura, Megumi and Notake, Chiemi and Aoki, Satoko and Okano, Kazunori and Yoshino, Takayuki},
  title = {A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02684-z}
}
Kostenlos starten →